Boston Scientific vs Solventum
BSX and SOLV side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BSX and SOLV compare
Boston Scientific is the larger company, worth 4.2 times as much as Solventum ($64.1B against $15.1B).
On earnings, Boston Scientific is cheaper: it trades at 18.7× trailing earnings, against 99.8× for Solventum.
Boston Scientific grew revenue faster over the last twelve months (8.9% versus −2.8% for Solventum).
Boston Scientific scores higher on the StockData Score (14 against 6 for Solventum), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BSX | SOLV |
|---|---|---|
| Size and price | ||
| Market cap | $64.1B | $15.1B |
| Share price | $44.20 | $88.81 |
| Change, 1 year | −56.9% | 20.2% |
| Change, 5 years | 7.7% | – |
| Beta (5Y) | 0.78 | 0.51 |
| Employees | 59K | 10K |
| StockData Score | ||
| Total score | 14 (better) | 6 |
| Valuation score | 6 (better) | 1 |
| Growth score | 3 (better) | 2 |
| Performance score | 1 | 2 (better) |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 18.7× (better) | 99.8× |
| P/S | 3.0× | 1.9× (better) |
| P/B | 2.5× (better) | 3.1× |
| EV/EBITDA | 14.1× (better) | 20.2× |
| P/FCF | 19.2× | – |
| PEG | 0.30 (better) | 22.14 |
| FCF yield | 5.2% (better) | 0.00% |
| Fair value | $89.74 | $45.74 |
| Margin of safety | 50.7% (better) | −94.2% |
| Growth | ||
| Revenue growth (TTM) | 8.9% (better) | −2.8% |
| Revenue growth, 5Y average | 15.2% | – |
| Net income growth (TTM) | – | −89.8% |
| EPS growth (TTM) | 26.2% (better) | −89.8% |
| Profitability | ||
| Gross margin | 69.1% (better) | 54.8% |
| Operating margin | 18.7% (better) | 5.6% |
| Net margin | – | 1.9% |
| FCF margin | 15.8% (better) | 0.00% |
| Return on equity | – | 3.2% |
| Return on invested capital | 10.6% (better) | 4.7% |
| Financial health | ||
| Debt / equity | 0.47 (better) | 1.05 |
| Net debt / EBITDA | 2.11 (better) | 4.74 |
| Interest coverage | 10.5× | – |
| Current ratio | 1.36 (better) | 1.03 |
| Altman Z-score | 3.03 (better) | 1.85 |
| Piotroski F-score | – | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 92.1% | 75.0% |
| Held by insiders | 0.20% | 30.3% |
| Insider net buying, 12 months | −$6.8M | $100K (better) |
| Superinvestors holding | 1 | 2 (better) |
| Short interest, % of float | 2.4% | 4.3% |
Go deeper
- BSX stock overview
- BSX income statement
- BSX valuation and score
- SOLV stock overview
- SOLV income statement
- SOLV valuation and score
Other comparisons
- BAX vs BSX
- BAX vs SOLV
- BDX vs BSX
- BSX vs GEHC
- BSX vs MDLN
- BSX vs MDT
- BSX vs MMM
- BSX vs SYK
- MDLN vs SOLV
- MMM vs SOLV
- RMD vs SOLV
- SOLV vs TFX
For information only, not investment advice. Check the source filings before relying on any figure.